Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Sonja Zweegman, MD PhD, Jim Cavet, FRCPath, Kwee Yong, Lydia Lee, Jim Faulkner, Ekaterini Kotsopoulou, Muhammad Al-Hajj, Simon Thomas, PhD, Shaun P Cordoba, PhD, Martin Pule, MD, Virginie Cerec, PhD, Vijay G R Peddareddigari, Nushmia Z Khokhar, MD, Tobias F Menne, MD PhD FRCPath

Blood (2019) 134 (Supplement_1): 3112.

https://doi.org/10.1182/blood-2019-126689

Published: 2019

Journal Articles

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Rakesh Popat, Sarah R Brown, Avie-Lee Tillotson, Fiona Collinson, Louise M Flanagan, Cathy D Williams, Kwee L Yong, Gordon Cook, MD PhD, Matthew W Jenner, MD, Martin Kaiser, Jim Cavet, FRCPath, Dima El-Sharkawi, MD, Chin-Hin Ng, MD MRCP, FRCPATH, Eric Low, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2016) 128 (22): 3321.

https://doi.org/10.1182/blood.V128.22.3321.3321

Published: 2016

Journal Articles

Therapeutic Cyclosporine Exposure Measured As Area Under the Curve (AUC) Significantly Influences the Outcome after Allogeneic Hematopoetic Stem Cell Transplant (alloHSCT)

Samar Kulkarni, MD MRCP, FRCPath, John Murray, BSc (hons), MSc, Michael Dennis, FRCPath, Jim Cavet, FRCPath, Anna Z Castleton, FRCPath, Tim Somervaille, MDPhD, Daniel Wiseman, FRCPath, Joanna Tomlins, MSc, Adrian Bloor

Blood (2016) 128 (22): 2237.

https://doi.org/10.1182/blood.V128.22.2237.2237

Published: 2016

Journal Articles

Retrospective Analysis of Seasonal Respiratory Viral Infections (SRVI) in Hematology, Lymphoma and Oncology Patients

Samar Kulkarni, MD MRCP, FRCPath, Stephanie Michail, MBBS, Charlotte Smith, MSc, Joanna Tomlins, MSc, John Murray, BSc (hons), MSc, Michael Dennis, FRCPath, Jim Cavet, FRCPath, Tim Somervaille, MD PhD, Daniel Wiseman, FRCPath, Anna Z Castleton, FRCPath, Adrian Bloor

Blood (2016) 128 (22): 4608.

https://doi.org/10.1182/blood.V128.22.4608.4608

Published: 2016

Journal Articles

Higher Incidence and Risk of Developing Second Solid Cancers (SSC) after Haematopoetic Stem Cell Transplantation (HSCT) As Compared to General Population

Samar Kulkarni, MD MRCP, FRCPath, John Murray, BSc (hons), MSc, Charlotte Smith, MSc, Stephanie Cleaver, RGN, Michael Dennis, FRCPath, Jim Cavet, FRCPath, Tim Somervaille, MD PhD, Anna Z Castleton, FRCPath, Daniel Wiseman, FRCPath, Joanna Tomlins, MSc, Kaz Mamat, MRCP, Angie Leather, MSc, Rita Angelica, BSc, Adrian Bloor

Blood (2016) 128 (22): 4610.

https://doi.org/10.1182/blood.V128.22.4610.4610

Published: 2016

Journal Articles

Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial

John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, David A Cairns, Cathy Williams, A Hockaday, J. D. Cavenagh, MD MRCP, John A Snowden, MD FRCP, FRCPath, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, Guy Pratt, MD, Sally Chown, Earnest Heartin, Sheila J.M. O'Connor, Julia Brown, PhD, Curly Morris, MD, Gordon Cook, MD PhD

Blood (2015) 126 (23): 1981.

https://doi.org/10.1182/blood.V126.23.1981.1981

Published: 2015

Journal Articles

Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience

Sam H Ahmedzai, MBChB BSc FRCP, John A Snowden, MD FRCP, FRCPath, Angela Cox, BA MA PhD, David A Cairns, Cathy D Williams, Anna Hockaday, Jamie Cavenagh, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, Julia Brown, PhD, Curly Morris, MD, Gordon Cook, MD PhD

Blood (2015) 126 (23): 3180.

https://doi.org/10.1182/blood.V126.23.3180.3180

Published: 2015

Journal Articles

Incidence of Thrombotic Complications with Use of Peg-Asparginase in Treatment for Acute Lymphoblastic Leukemia (ALL) in Adults and Young Adolescent Patients

David JM Routledge, MRCP, Joanna Tomlins, MSc, Adrian Bloor, FRCPath, Kaz Mamat, MRCP, Michael Dennis, FRCPath, Jim Cavet, FRCPath, Tim Somervaille, Sven Armin Sommerfeld, MRCP, Samar Kulkarni, FRCPath

Blood (2015) 126 (23): 4864.

https://doi.org/10.1182/blood.V126.23.4864.4864

Published: 2015

Journal Articles

Use of CMV Unselected Blood Products Does Not Increase the Risk of CMV Reactivation in Patients Undergoing Hematopoetic Stem Cell Transplant (HSCT)

Jayne Peters, MRCP, Jonathon Elliott, MRCP, Adrian Bloor, FRCPath, Michael Dennis, FRCPath, John Murray, MSc, Jim Cavet, FRCPath, Tim Somervaille, Sven Armin Sommerfeld, MRCP, Ken Mutton, FRCPath, Kaz Mamat, MRCP, Malcolm Guiver, PhD, Samar Kulkarni, FRCPath

Blood (2015) 126 (23): 2346.

https://doi.org/10.1182/blood.V126.23.2346.2346

Published: 2015

Journal Articles

A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial

Gordon Cook, MD PhD, Cathy Williams, David A Cairns, Anna Hockaday, Jamie Cavenagh, John A Snowden, MD FRCP, FRCPath, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, Guy Pratt, MD, Sally Chown, Earnest Heartin, Sheila J.M. O'Connor, John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, Julia Brown, PhD, Curly Morris, MD

Blood (2015) 126 (23): 394.

https://doi.org/10.1182/blood.V126.23.394.394

Published: 2015

Journal Articles

Population Based Study of Cytogenetic Abnormalities in Addition to Philadelphia (Ph) Chromosome in Patients with Chronic Myeloid Leukaemia (CML) and Impact on Survival

Jo Tomlins, MSc, Nick Telford, PhD, Mike Dennis, FRCPath, Tim Somervaille, FRCPath, Adrian Bloor, PhD FRCPath, Jim Cavet, FRCPath, Mike Green, PhD, Sven Armin Sommerfeld, MRCP, John Murray, RGN, MSc, Samar Kulkarni, FRCPath

Blood (2014) 124 (21): 4567.

https://doi.org/10.1182/blood.V124.21.4567.4567

Published: 2014

Journal Articles

Advanced Age at Transplant Increases the Risk of Second Solid Malignancy (SSM) after Haematopoetic Stem Cell Transplantation (HSCT)

John Murray, RGN, MSc, John Chadwick, MRCP, Adrian Bloor, PhD FRCPath, Jim Cavet, FRCPath, Mike Dennis, FRCPath, Tim Somervaille, FRCPath, Sven Armin Sommerfeld, MRCP, John Eliott, MRCP, Siobhan Muthia, MRCP, Angie Leather, RGN BSc, Rita Angelica, RGN BSc, Rachel Brown, MRCP, Jo Tomlins, MSc, Samar Kulkarni, FRCPath

Blood (2014) 124 (21): 3952.

https://doi.org/10.1182/blood.V124.21.3952.3952

Published: 2014

Journal Articles

Outcome Of Escherichia Coli (E.coli) Blood Stream Infections (BSI) In Haematology-Oncology Patients- Hematopoetic Stem Cell Transplantation (HSCT) Is Not Associated With Increased Mortality

Zena Salih, MRCP, Felicity Fergusson, MRCP, Andrew Stevens, MBBS, Katalina Balassa, MD, Theingi Yin, MRCP, Kirsty Dodgson, FRCPath, Kaczmarsky Ed, FRCPath, Malcolm Guiver, PhD, Ken Mutton, FRCPath, Mike Dennis, FRCPath, Jim Cavet, FRCPath, Tim Sommervaile, FRCPath, Jo Tomlins, RGN, BN, MSc,, John Murray, RGN, MSc, Adrian Bloor, PhD, FRCP, FRCPath, Samar Kulkarni, MD, MRCP, FRCPath

Blood (2013) 122 (21): 5455.

https://doi.org/10.1182/blood.V122.21.5455.5455

Published: 2013

Journal Articles

Incidence and Risk Factors For Pneumocystis Jirovecii pneumonia (PCP) Following Haematopoetic Stem Cell Transplant (HSCT)

Samar Kulkarni, MD, MRCP, FRCPath, Mike Dennis, FRCPath, Jim Cavet, FRCPath, John Murray, RGN, MSc, Jo Tomlins, RGN, BN, MSc, Zena Salih, MRCP, Martin Scott, MRCP, Katalina Balassa, MD, Malcolm Guiver, PhD, Ken Mutton, FRCPath, Ed Kaczmarsky, FRCPath, David Kay, MSc, Tim Sommerville, FRCPath, Kirsty Dodgson, FRCPath, Sven Armin Sommerfeld, MRCP, Adrian Bloor, PhD, FRCP, FRCPath

Blood (2013) 122 (21): 4641.

https://doi.org/10.1182/blood.V122.21.4641.4641

Published: 2013

Journal Articles

Identifying An Optimally Effective But Tolerable Dose Of Bendamustine In Combination With Thalidomide and Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma

Stephen A Schey, MD, Kwee L Yong, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, Faith E Davies, MD, Gareth J Morgan, MD PhD, James D. Cavenagh, MD, Gordon Cook, MD, PhD, Mark Cook, Avie-Lee Coney, Sarah Brown, PhD, Louise M Flanagan, PhD, Walter Gregory, PhD, Jim Cavet, FRCPath

Blood (2013) 122 (21): 286.

https://doi.org/10.1182/blood.V122.21.286.286

Published: 2013

Journal Articles

A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, J. D. Cavenagh, MD, MRCP, John A Snowden, MD, FRCP, FRCPath, Christopher Parrish, MD, John Ashcroft, Kwee L Yong, PhD, Jim Cavet, FRCPath, Hannah Hunter, MB, FRCPath, MRCP, Jennifer Bird, Sheila J O'Connor, Julia MB Brown, Treen Morris

Blood (2013) 122 (21): 765.

https://doi.org/10.1182/blood.V122.21.765.765

Published: 2013

NARROW

Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Therapeutic Cyclosporine Exposure Measured As Area Under the Curve (AUC) Significantly Influences the Outcome after Allogeneic Hematopoetic Stem Cell Transplant (alloHSCT)

Retrospective Analysis of Seasonal Respiratory Viral Infections (SRVI) in Hematology, Lymphoma and Oncology Patients

Higher Incidence and Risk of Developing Second Solid Cancers (SSC) after Haematopoetic Stem Cell Transplantation (HSCT) As Compared to General Population

Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience

Incidence of Thrombotic Complications with Use of Peg-Asparginase in Treatment for Acute Lymphoblastic Leukemia (ALL) in Adults and Young Adolescent Patients

Use of CMV Unselected Blood Products Does Not Increase the Risk of CMV Reactivation in Patients Undergoing Hematopoetic Stem Cell Transplant (HSCT)

A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial

Population Based Study of Cytogenetic Abnormalities in Addition to Philadelphia (Ph) Chromosome in Patients with Chronic Myeloid Leukaemia (CML) and Impact on Survival

Advanced Age at Transplant Increases the Risk of Second Solid Malignancy (SSM) after Haematopoetic Stem Cell Transplantation (HSCT)

Outcome Of Escherichia Coli (E.coli) Blood Stream Infections (BSI) In Haematology-Oncology Patients- Hematopoetic Stem Cell Transplantation (HSCT) Is Not Associated With Increased Mortality

Incidence and Risk Factors For Pneumocystis Jirovecii pneumonia (PCP) Following Haematopoetic Stem Cell Transplant (HSCT)

Identifying An Optimally Effective But Tolerable Dose Of Bendamustine In Combination With Thalidomide and Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma

A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only